कंपनी का अवलोकन
BioVie Inc. operates as a clinical-stage biopharmaceutical entity dedicated to developing therapeutic interventions for neurological, neurodegenerative disorders, and advanced liver disease within the United States market. The company functions within the broader Healthcare sector, specifically specializing in the Biotechnology industry, where innovation in drug discovery and clinical trial execution defines competitive positioning. As of the latest reported data, BioVie Inc. maintains a market capitalization of $10.86M and employs a workforce of 13 individuals to advance its research pipeline. The combination of a relatively small market cap and the absence of reported annual revenue figures suggests that the company is in an early-stage development phase, prioritizing capital allocation toward clinical progress rather than commercial scaling. This financial profile indicates an asset-light operational model typical of clinical-stage firms that have not yet achieved significant product commercialization or revenue generation from their drug therapies.
वित्तीय स्वास्थ्य
The company's financial statements reveal a Net Income of $-17,478,136 over the trailing twelve months, accompanied by an EBITDA of $-17,968,812, while reported Revenue for the same period is N/A. The substantial gap between the reported Net Income and EBITDA figures, alongside the lack of revenue data, highlights a cost structure heavily weighted toward research and development expenses rather than cost of goods sold associated with large-scale manufacturing. Free Cash Flow stands at $-8,277,755, indicating that the company is currently burning cash to fund its operations and pipeline advancement rather than generating liquidity from core business activities. All three margin metrics—Gross Margin, Operating Margin, and Profit Margin—are recorded at 0.0%, which reflects the typical accounting treatment for early-stage biotechnology companies that have not yet realized commercial sales to calculate meaningful margins. The balance sheet shows a Cash position of $20.54M against a Debt obligation of $314,915, resulting in a Debt to Equity ratio of 1.64, which suggests a leveraged capital structure relative to its equity base despite the low absolute debt amount. The Current Ratio is listed at 7.25, implying strong short-term liquidity coverage relative to current liabilities, although the absence of revenue makes the utility of this liquidity dependent on future fundraising or milestone achievements. Return on Equity is -80.7% and Return on Assets is -47.2%, metrics that clearly indicate that management is currently generating negative returns on shareholder capital and asset base due to the pre-revenue nature of the business.
मूल्यांकन आकलन
Valuation metrics for BioVie Inc. present a complex picture given the lack of traditional profitability data, with the P/E Ratio (TTM) listed as N/A and a Forward P/E of -0.33. The negative Forward P/E implies that the market is pricing in significant losses or expects earnings to be negative in the near term, making the difference between trailing and forward metrics indicative of anticipated continued financial deficits rather than an earnings turnaround. The Price to Book ratio is 0.56, suggesting that the market values the company's equity at less than half its book value, which often occurs when investors discount the value of intangible assets like clinical trial data and intellectual property. Since Revenue is N/A, the Price to Sales ratio is also N/A, and the EV/EBITDA stands at 0.52, a figure that, while low, must be interpreted with caution as it is derived from negative earnings, suggesting the market is not applying a traditional multiple for growth but rather a liquidation or deep discount value. The stock has traded between a 52-Week High of $13.20 and a 52-Week Low of $1.06, providing a wide volatility range that reflects the speculative nature of investing in clinical-stage biotech assets. The Beta is 0.56, indicating that the stock's price volatility is historically less than half that of the broader market, a characteristic often seen in small-cap biotechnology firms that may be less sensitive to general market movements but highly sensitive to specific clinical trial outcomes.
Growth & Income
Growth metrics for BioVie Inc. show Revenue Growth (YoY) and Earnings Growth (YoY) both listed as N/A, reflecting the absence of historical revenue data required to calculate year-over-year percentage changes. In the absence of revenue growth data, it is impossible to determine if earnings are growing faster or slower than sales, as the company has not yet transitioned from a research-focused entity to a revenue-generating commercial operation. The company does not pay dividends, evidenced by a Dividend Yield of N/A and a Payout Ratio of 0.0%, meaning the firm reinvests all available resources, including its cash reserves, back into its drug development pipeline rather than distributing income to shareholders. Consequently, the overall growth and income profile for BioVie Inc. is characterized entirely by capital appreciation potential derived from pipeline milestones rather than current cash flow or dividend income, representing a high-risk, high-potential-return investment strategy suitable for investors with a long-term horizon and tolerance for pre-commercialization volatility.